← Research ProtocolsTirzepatide
STUDIED EXPOSURE MAP / 2022
Tirzepatide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 3NEW ENGLAND JOURNAL OF MEDICINESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
5 mg
SC · once weekly
10 mg
SC · once weekly
15 mg
SC · once weekly
Context: Target trial doses are shown. The trial included a structured escalation period, which is part of the protocol and should not be simplified into consumer instructions.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide Once Weekly for the Treatment of Obesity
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2022
01 / DESIGNPhase 3 · double-blind · randomized · placebo-controlled
02 / POPULATION / MODELAdults with obesity or overweight without diabetes in the primary trial population
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAME72 weeks · including 20-week dose escalation
05 / PRIMARY QUESTIONPercent change in body weight and categorical weight-loss endpoints
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.